pharmaphorum

AUGUST 18, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

pharmaphorum

SEPTEMBER 2, 2020

But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.

Trials 111

Trials RNA Pharma Companies Clinical Trials 111

pharmaphorum

JANUARY 12, 2021

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology.

RNA 95

RNA Production Development Pharma Companies 95

pharmaphorum

JANUARY 6, 2021

Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. — Tinglong Dai (@TinglongDai) January 5, 2021.

DNA 116

DNA Branding Vaccination Vaccine 116

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. How big pharma tackles rare diseases. It’s a different business model, if you will,” Miquel said. “So So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

AUGUST 18, 2020

An important feature of the test that contributes to its reduced cost is the fact that sample processing does not require a separate nucleic acid (RNA) extraction step. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

pharmaphorum

NOVEMBER 23, 2021

The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 million in milestones – covers rights to ARO-HSD, Arrowhead’s RNA interference drug targeting an enzyme called HSD17B13 that seems to contribute to the pathology of NASH and other liver diseases.

Sales 52

Sales Drugs Trials RNA 52

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. Biotech and AI companies founded by purely tech professionals often opt to bring in pharma executives with insider knowledge further down the line.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. RNA technology is not new nor has its potential been surprising. RNA in the Making. So why did this perceived RNA ‘revolution’ take so long?

Life Science 98

Life Science RNA Vaccination Vaccine 98

pharmaphorum

JANUARY 10, 2022

The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individual treatments. Prior to the pandemic, biotech had a market cap of around $6.5bn whereas, at present, it is now valued at approximately $144bn.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

Delveinsight

JANUARY 8, 2021

HDV is nothing but a defective RNA virus, a satellite of the helper Hepatitis B virus (HBV) that needs the HBsAg of the hepatitis B virus (HBV) for virion assembly, release, and transmission. HDV infection can be acute or lead to chronic, long-term illness.

Marketing 52

Marketing RNA Development Pharma Companies 52

Drug Discovery World

JANUARY 21, 2024

He will also explain the importance of this innovation as a way to mitigate the high failure rates in clinical trials, which historically see 92% of drugs fail despite passing animal tests, leading to significant financial and time losses in the industry (approximately $53 billion for pharma companies annually).

Protein 52

Protein Vaccination Vaccine Development 52

pharmaphorum

DECEMBER 21, 2020

Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. He told pharmaphorum: “They are very good doctors, scientists and entrepreneurs.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Delveinsight

FEBRUARY 8, 2021

The major factors shaping the market outlook include prevalence, monopoly of a pharma company, diagnostics and screening methodologies, entry of other market players in the Cystic Fibrosis market domain, as well as restraints. and Verona Pharma’s RPL 554.

Marketing 52

Marketing Production Development RNA 52

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market. Rare disease progress.

Marketing 96

Marketing Gene Silencing Gene Drugs 96

Delveinsight

AUGUST 6, 2020

The present hATTR treatment market constitutes compounds that stabilize the TTR tetramers, a TTR-directed small interfering RNA, and a TTR-directed antisense oligonucleotide, along with supportive therapies. The past years have witnessed a shift from off-label and symptomatic therapies to approved TTR stabilizers and gene-silencing therapies.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. This year has seen some major deals announced by big pharma companies.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

XTalks

DECEMBER 13, 2023

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. Notably, Twist Bioscience continues to enhance its NGS portfolio by introducing a new RNA sequencing portfolio, catering to the extensive research market.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

MARCH 11, 2022

However, the financial success that has been delivered to certain companies working on vaccine development has emerged after a long period where investing in the space had become increasingly unpopular among the larger pharma companies.

Vaccination 81

Vaccination Vaccine Development Manufacturing 81

pharmaphorum

DECEMBER 7, 2021

The deal – which is weighted heavily towards neuroscience with just one cancer programme covered – is the second between Recursion and a big pharma company in the space of two days, coming on the heels of a smaller alliance with Bayer that will look for new fibrosis drugs.

Drugs 59

Drugs RNA Pharma Companies Protein 59

pharmaphorum

AUGUST 23, 2022

Explaining why Ampligen may prove effective, the spokesperson said, “Ampligen is a selective TLR3 agonist which — to put it very simply — works to activate immune cells, shut down protein replication and chew-up viral RNA, all of which can help stop the virus from replicating and hopefully even eradicate it.

Vaccination 134

Vaccination Vaccine Development Trials 134

Drug Discovery World

AUGUST 8, 2023

According to a report by Deloitte, globally India is the third largest in the world by volume and 11th by value, comprising over 3,000 pharma companies and 10,500 manufacturing facilities 2. To many, the country is referred to as the ‘pharmacy of the world’. So, what is driving this success, and will it continue?

Research 52

Research Drugs Genome Genomics 52

Drug Discovery World

NOVEMBER 15, 2022

To accelerate drug development timelines, biotechs and pharma companies may choose to outsource some or all parts of antibody discovery and optimisation to DNA synthesis technology partners equipped with the tools and techniques to get reliable results faster.

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

JANUARY 3, 2023

Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery.

DNA 52

DNA Protein Drugs RNA 52

The Pharma Data

MAY 13, 2021

Unfortunately, I learned the hard way that the “Big Pharma” companies don’t care about their patients. Stimulates DNA and RNA synthesis. Why do doctors prescribe drugs which are so powerful they require a second set of medication just to deal with the side effects! It’s all about the bottom line, at any cost.

Pharmacy 52

Pharmacy Production Doctors Doctor 52

Pharmaceutical Technology

DECEMBER 19, 2022

Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says.

Life Science 173

Life Science Manufacturing Medicine Production 173